Analysts' ratings for PROCEPT BioRobotics (NASDAQ:PRCT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...

PROCEPT BioRobotics recently reported two major milestones in its WATER IV prostate cancer program, completing enrollment in the randomized WATER IV RP trial comparing Aquablation therapy with radical ...

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...

PROCEPT BioRobotics (NASDAQ:PRCT) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Chicago Capital added 969,592 shares of PROCEPT BioRobotics, an estimated $27.32 million trade based on the average share price in the first quarter of 2026. Quarter-end position value rose by $16.57 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE)-- PROCEPT BioRobotics® Corporation (the "Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...